Cardiff Oncology Set to Present at Investor Conference
Cardiff Oncology, Inc. (NASDAQ: CRDF), a pioneering clinical-stage biotechnology company, recently announced an important opportunity to connect with investors through Sidoti’s Year-End Virtual Investor Conference. This significant event is scheduled for the early part of December, where company leadership will present their latest advancements in cancer therapies.
Key Presentation Details
The presentation will be led by Mark Erlander, PhD, the Chief Executive Officer of Cardiff Oncology. On the second day of the conference, Dr. Erlander will provide insights into the company’s innovative approaches and future plans in cancer treatment. The scheduled time for this pivotal presentation is set for 4:00 PM ET on the second day.
What to Expect from the Presentation
Attendees can expect an engaging discussion that highlights Cardiff Oncology’s research and the potential impact of their lead asset, onvansertib. This PLK1 inhibitor represents a remarkable advancement in therapeutic strategies designed to tackle various types of hard-to-treat cancers.
The Role of Onvansertib in Cancer Treatment
Onvansertib is at the forefront of Cardiff Oncology’s research, specifically targeting RAS-mutated metastatic colorectal cancer (mCRC). Its effectiveness is being tested in combination with standard care therapies to enhance patient outcomes. Additionally, ongoing trials with this innovative drug extend into other challenging cancer types, including small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC).
Groundbreaking Research and Development
Cardiff Oncology’s research focuses on overcoming treatment resistance that many patients face. Their cutting-edge research aims to utilize PLK1 inhibition effectively, potentially leading to better clinical outcomes compared to standard treatment alone. The company’s development strategy is not just about creating new drugs, but about understanding tumor vulnerabilities to tailor effective therapies.
Importance of Investor Engagement
Investor conferences like Sidoti’s are crucial for fostering relationships between companies and their shareholders. They offer an essential platform for management to share updates on significant developments, study advancements, and the overall direction of the company.
Key Contacts at Cardiff Oncology
For those interested in further details or inquiries, Cardiff Oncology provides contact information for key executives. James Levine, the Chief Financial Officer, is available for investor-related inquiries, while media contacts like Amy Bonanno from Lyra Strategic Advisory can address broader questions about the company and its public presence.
Looking Ahead
As Cardiff Oncology prepares for the upcoming conference, excitement builds around their prospects in the field of biotechnology and cancer treatment. The focus on innovative therapies promises to open new doors for patients facing formidable cancer diagnoses.
Frequently Asked Questions
What is Cardiff Oncology known for?
Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer, primarily using PLK1 inhibition.
When will the presentation take place?
The presentation by Mark Erlander is scheduled for 4:00 PM ET on December 11.
How can I access the live presentation?
Interested parties can register for and access the live webcast through the Cardiff Oncology website under the Events section.
What areas does Cardiff Oncology research cover?
The company targets various cancers, particularly RAS-mutated metastatic colorectal cancer and other difficult-to-treat cancers, through innovative therapies.
Who can I contact for more information about Cardiff Oncology?
For inquiries, James Levine, the Chief Financial Officer, can be contacted directly at 858-952-7670.
